Your browser doesn't support javascript.
loading
Desmopressin acetate use in von Willebrand's disease: a survey on current practices in Brazil
Lopes, Maria Sueli da Silva Namen; Rezende, Suely Meireles.
Afiliação
  • Lopes, Maria Sueli da Silva Namen; Universidade Federal de Minas Gerais - UFMG. BR
  • Rezende, Suely Meireles; Universidade Federal de Minas Gerais - UFMG. BR
Hematol., Transfus. Cell Ther. (Impr.) ; 43(1): 43-49, Jan.-Mar. 2021. tab, ilus
Article em En | LILACS | ID: biblio-1154294
Biblioteca responsável: BR408.1
Localização: BR408.1
ABSTRACT
ABSTRACT

Introduction:

von Willebrand's disease (VWD) is the most common inherited bleeding disorder. The 1-desamino-8-d-arginine vasopressin (DDAVP) is the treatment of choice for most responsive patients with VWD. The aim of this study was to evaluate DDAVP use in the management of VWD.

Method:

We implemented a survey targeting medical doctors involved in the management of VWD in Brazil. Data was collected during a national congress on Hematology in November 2017. Main

results:

A total of 51/80 (63.8%) questionnaires were collected. Most participants (76.2%) were hematologists who assisted adult patients and approximately 60% worked at hemophilia treatment centers (HTCs). Approximately half of participants who reported treating patients with VWD, assisted on average, less than 5 patients per month, and approximately 60% declared not having used any DDAVP for treating VWD in the previous year. However, most participants (70%) prescribed FVIII-containing VWF concentrate (VWF/FVIII) for 1-10 patients in the previous year. More than 80% of the participants recognized the main indications for DDAVP. Physicians who recognized indication for DDAVP for type 1 VWD more often had prescribed DDAVP in previous year (p = 0.03). Barriers for prescribing DDAVP varied and included unavailability of laboratory facilities and consumables for DDAVP testing and lack of skills on its prescription.

Conclusion:

The DDAVP is currently underused in Brazil, as opposed to the excessive use of VWF/FVIII in VWD patients. We suggest the adoption of measures targeting educational and auditing programs. Furthermore, availability of laboratory reagents is needed to evaluate response and increment the correct use of DDAVP.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Doenças de von Willebrand / Desamino Arginina Vasopressina País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hematol., Transfus. Cell Ther. (Impr.) Assunto da revista: Hematologia / TransfusÆo de Sangue Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Doenças de von Willebrand / Desamino Arginina Vasopressina País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hematol., Transfus. Cell Ther. (Impr.) Assunto da revista: Hematologia / TransfusÆo de Sangue Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil